Xeris Biopharma Holdings Inc’s recently made public that its Director Fairley Ricki Louise acquired Company’s shares for reported $0.28 million on May 09 ’25. In the deal valued at $4.90 per share,56,667 shares were bought.
Then, Hecht Beth sold 40,000 shares, generating $217,244 in total proceeds. Upon selling the shares at $5.43, the insider now owns 1,353,510 shares.
Before that, Hecht Beth bought 40,000 shares. Xeris Biopharma Holdings Inc shares valued at $205,600 were divested by the Officer at a price of $5.14 per share.
Piper Sandler downgraded its Xeris Biopharma Holdings Inc [XERS] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in late March with a ‘”an Outperform”‘ rating. Craig Hallum began covering XERS with “Buy” recommendation on August 28, 2023. Jefferies started covering the stock on October 21, 2022. It rated XERS as “a Buy”.
Price Performance Review of XERS
On Tuesday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock fall -1.01% to $4.90. Over the last five days, the stock has gained 13.95%. Xeris Biopharma Holdings Inc shares have risen nearly 44.54% since the year began. Nevertheless, the stocks have risen 160.64% over the past one year. While a 52-week high of $6.07 was reached on 03/26/25, a 52-week low of $1.77 was recorded on 01/13/25. SMA at 50 days reached $4.68, while 200 days put it at $3.52.
Levels Of Support And Resistance For XERS Stock
The 24-hour chart illustrates a support level at 4.82, which if violated will result in even more drops to 4.73. On the upside, there is a resistance level at 5.01. A further resistance level may holdings at 5.11. The Relative Strength Index (RSI) on the 14-day chart is 56.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.34, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 32.65%. Stochastics %K at 73.20% indicates the stock is a holding.
The most recent change occurred on April 28, 2022 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $6.50 price target.
